Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats.
The objective of this study was to investigate the contribution of norfloxacin blood-brain barrier (BBB) transport to its delayed electroencephalogram (EEG) effect in rats. Norfloxacin was injected as a bolus dose of 150 mg kg(-1). Blood samples were collected for total norfloxacin plasma concentration measurements. The corresponding unbound levels were determined in brain extracellular fluid (ECF) using microdialysis. Quantitative EEG recording was conducted during 9 h post-dose. Brain ECF norfloxacin concentrations were much lower than plasma levels (AUC ratio=9.7+/-2.8%) but peaked very early, and concentration versus time profiles were parallel in both biological fluids. The best pharmacokinetic (PK) modelling was obtained by considering that ECF concentrations were part of the central compartment, with a proportionality factor. The peak of EEG effect was delayed and the effect versus plasma concentration curves exhibited a dramatic hysteresis. A PK-pharmacodynamic (PD) effect compartment model with a spline function to describe the relationship between effect and concentration at the effect site successfully described the data. Comparisons of PK-PD parameters estimated from plasma and ECF concentrations show that most of the delayed norfloxacin EEG effect is not due to BBB transport, but also that PD parameters derived from plasma data must be carefully interpreted when drug distribution at the effect site is restricted, as may often be the case for centrally acting drugs.
Chenel
Marylore
M
EE Médicaments anti-infectieux et barrière hémato-encéphalique, PBS, Faculté de Médecine & Pharmacie, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, France.
Marchand
Sandrine
S
Dupuis
Antoine
A
Lamarche
Isabelle
I
Paquereau
Joël
J
Pariat
Claudine
C
Couet
William
W
D000818:Animals; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism; D003292:Convulsants / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D004569:Electroencephalography / Q000187:drug effects*; D008297:Male; D008959:Models, Neurological; D009643:Norfloxacin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D003292:Convulsants; D009643:Norfloxacin